Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter E Westerweel

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
European Journal of Haematology|July 13, 2019
Treatment strategies for polycythemia vera: Observations in a Dutch "real-world" cohort studyClaire van de Ree-Pellikaan, Arne de Kreuk, Cees G Schaar, et al.
Research and Practice in Thrombosis and Haemostasis|July 2, 2024
Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trialEva N Hamulyák, Hanke M G Wiegers, Barbara A Hutten, et al.
Frontiers in Oncology|September 12, 2025
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trialFabio Efficace, Laura Cannella, Isabella Capodanno, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 20, 2018
Performance of idarucizumab as antidote of dabigatran in daily clinical practiceSake J van der Wall, Nienke van Rein, Bart van den Bemt, et al.
Leukemia|July 21, 2023
Prognosis of IGLV3-21<sup>R110</sup> chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysisPaul J Hengeveld, Hendrik Veelken, Cornelis A M van Bergen, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
Annals of Hematology|April 29, 2023
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effectsInge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, et al.
Haematologica|October 2, 2025
Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO studyDina Nienke Lokhorst, Yolba Smit, Bart J F Van den Bemt, et al.
Hemasphere|September 21, 2023
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLLPaul J Hengeveld, P Martijn Kolijn, Jeroen A A Demmers, et al.
Leukemia|May 18, 2022
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21<sup>R110</sup>Paul J Hengeveld, Y Emre Ertem, Julie M N Dubois, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
European Journal of Haematology|July 13, 2019
Treatment strategies for polycythemia vera: Observations in a Dutch "real-world" cohort studyClaire van de Ree-Pellikaan, Arne de Kreuk, Cees G Schaar, et al.
Research and Practice in Thrombosis and Haemostasis|July 2, 2024
Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trialEva N Hamulyák, Hanke M G Wiegers, Barbara A Hutten, et al.
Frontiers in Oncology|September 12, 2025
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trialFabio Efficace, Laura Cannella, Isabella Capodanno, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 20, 2018
Performance of idarucizumab as antidote of dabigatran in daily clinical practiceSake J van der Wall, Nienke van Rein, Bart van den Bemt, et al.
Leukemia|July 21, 2023
Prognosis of IGLV3-21<sup>R110</sup> chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysisPaul J Hengeveld, Hendrik Veelken, Cornelis A M van Bergen, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
Annals of Hematology|April 29, 2023
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effectsInge G P Geelen, Stein-Erik Gullaksen, Mette M Ilander, et al.
Haematologica|October 2, 2025
Interim analysis of a multicenter study on patient-guided dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: the RODEO studyDina Nienke Lokhorst, Yolba Smit, Bart J F Van den Bemt, et al.
Hemasphere|September 21, 2023
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLLPaul J Hengeveld, P Martijn Kolijn, Jeroen A A Demmers, et al.
Leukemia|May 18, 2022
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21<sup>R110</sup>Paul J Hengeveld, Y Emre Ertem, Julie M N Dubois, et al.
Pageof 11